Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 5 | 2022 | 82 | 0.690 |
Why?
|
| Kidney Transplantation | 9 | 2019 | 112 | 0.690 |
Why?
|
| Arteriovenous Shunt, Surgical | 4 | 2022 | 22 | 0.580 |
Why?
|
| Immunosuppressive Agents | 7 | 2019 | 113 | 0.550 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 2 | 0.400 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 14 | 0.400 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 13 | 0.400 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 20 | 0.400 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 34 | 0.390 |
Why?
|
| Stents | 1 | 2013 | 75 | 0.380 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2022 | 19 | 0.280 |
Why?
|
| Liver Transplantation | 2 | 2014 | 81 | 0.270 |
Why?
|
| Graft Survival | 6 | 2019 | 84 | 0.270 |
Why?
|
| Graft Rejection | 4 | 2019 | 63 | 0.260 |
Why?
|
| Mycophenolic Acid | 5 | 2019 | 12 | 0.260 |
Why?
|
| Tacrolimus | 5 | 2019 | 14 | 0.250 |
Why?
|
| Vascular Patency | 4 | 2022 | 17 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 2 | 2019 | 121 | 0.240 |
Why?
|
| Carrier Proteins | 2 | 2016 | 88 | 0.230 |
Why?
|
| Upper Extremity | 2 | 2016 | 52 | 0.230 |
Why?
|
| Treatment Outcome | 9 | 2022 | 2940 | 0.190 |
Why?
|
| Aneurysm | 1 | 2022 | 10 | 0.190 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 10 | 0.190 |
Why?
|
| Isoxazoles | 1 | 2002 | 5 | 0.190 |
Why?
|
| Cyclosporine | 3 | 2007 | 12 | 0.170 |
Why?
|
| Surgical Instruments | 1 | 2020 | 24 | 0.170 |
Why?
|
| Time Factors | 8 | 2022 | 1263 | 0.170 |
Why?
|
| Sirolimus | 3 | 2005 | 20 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 61 | 0.160 |
Why?
|
| Suture Techniques | 1 | 2020 | 112 | 0.160 |
Why?
|
| Pancreatic Elastase | 2 | 2016 | 5 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 83 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 28 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2022 | 2994 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2020 | 812 | 0.130 |
Why?
|
| Brachial Artery | 1 | 2016 | 6 | 0.130 |
Why?
|
| Radial Artery | 1 | 2016 | 6 | 0.130 |
Why?
|
| Male | 12 | 2020 | 12438 | 0.130 |
Why?
|
| Female | 12 | 2020 | 12935 | 0.120 |
Why?
|
| Humans | 14 | 2022 | 22913 | 0.110 |
Why?
|
| Creatinine | 5 | 2010 | 41 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Middle Aged | 10 | 2020 | 7895 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 37 | 0.100 |
Why?
|
| Risk Factors | 5 | 2022 | 1968 | 0.100 |
Why?
|
| Adult | 9 | 2020 | 6912 | 0.090 |
Why?
|
| Prosthesis Design | 1 | 2013 | 388 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 50 | 0.080 |
Why?
|
| Aged | 7 | 2020 | 7429 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2016 | 373 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 162 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 164 | 0.060 |
Why?
|
| Calcineurin Inhibitors | 2 | 2005 | 15 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 165 | 0.060 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 13 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2016 | 1495 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2014 | 227 | 0.050 |
Why?
|
| Prognosis | 2 | 2019 | 717 | 0.050 |
Why?
|
| Anemia | 1 | 2002 | 30 | 0.050 |
Why?
|
| Prednisone | 1 | 2002 | 64 | 0.050 |
Why?
|
| Cost Savings | 1 | 2020 | 29 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 107 | 0.040 |
Why?
|
| United States | 2 | 2016 | 1763 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1413 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 21 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 198 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2014 | 15 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 2 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 27 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 163 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 314 | 0.030 |
Why?
|
| Kidney | 2 | 2005 | 142 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 309 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 204 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 13 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 3 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2010 | 63 | 0.020 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2007 | 1 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 59 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 64 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 1414 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2007 | 238 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2005 | 35 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 186 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 95 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 370 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 17 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 163 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 64 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 163 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 624 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 290 | 0.010 |
Why?
|